A Prospective Cohort Study Assessing the Efficacy and Safety of Tarceva in 2nd Line in Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Non-Small Cell Lung Cancer
Both
Non-Small Cell Lung Cancer
Trial Information
A Prospective Cohort Study Assessing the Efficacy and Safety of Tarceva in 2nd Line in Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Histologically or cytologically confirmed advanced (Stage IIIB) or metastatic (Stage
IV) squamous non-small cell lung cancer after failure of first-line platinum-based
chemotherapy
- Patients for whom the treating physician has decided to initiate treatment with
Tarceva
Exclusion Criteria:
- Mixed non-small cell and small-cell lung carcinoma or mixed squamous cell carcinoma
with predominant adenocarcinoma component
- Current participation in a clinical trial evaluating an anticancer treatment
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Progression-free survival
Outcome Time Frame:
2 years
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
France: Commission Nationale de l'Informatique et des Libertés (CNIL)
Study ID:
ML28195
NCT ID:
NCT01659970
Start Date:
June 2012
Completion Date:
May 2014
Related Keywords:
- Non-Small Cell Lung Cancer
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|
